Stock analysts at Bloom Burton assumed coverage on shares of Medicenna Therapeutics (TSE:MDNA) in a research report issued to clients and investors on Wednesday, Price Targets.com reports. The brokerage set a “buy” rating and a C$11.00 price target on the stock. Bloom Burton’s price objective indicates a potential upside of 252.56% from the company’s previous close.
Separately, Maxim Group restated a “buy” rating and set a C$9.00 price objective on shares of Medicenna Therapeutics in a research note on Tuesday, September 14th.
MDNA stock opened at C$3.12 on Wednesday. The firm has a 50 day moving average of C$2.98 and a 200 day moving average of C$3.99. The stock has a market capitalization of C$167.68 million and a PE ratio of -7.46. The company has a quick ratio of 7.43, a current ratio of 7.51 and a debt-to-equity ratio of 0.07. Medicenna Therapeutics has a 52 week low of C$2.35 and a 52 week high of C$7.02.
Medicenna Therapeutics Corp., a clinical stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase 2b clinical trial for the treatment of recurrent glioblastoma (rGBM), as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors.
Featured Story: Purposes and Functions of the Federal Reserve
Receive News & Ratings for Medicenna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicenna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.